Press Releases & Statements

Investor Relations

Month Year

Month Year

Novavax Statement on Proof of COVID-19 Vaccine Requirements for PREVENT-19 Clinical Trial Participants in the U.S.
- Statement
- COVID-19
Sep 17, 2021
Novavax to Participate in University of Oxford Com-COV3 Study Comparing Mixed COVID-19 Vaccine Schedule in Adolescents
- COVID-19
Sep 16, 2021
Novavax Statement on Takeda Agreement to Provide 150 Million Doses of NVX-CoV2373 to the Government of Japan
- Statement
- COVID-19
Sep 10, 2021
Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza
- COVID-19
Sep 8, 2021
Novavax Statement on CDC Guidance Update for COVID-19 Clinical Trial Participants
- COVID-19
Aug 30, 2021
Novavax to Participate in OCTAVE-DUO Study to Evaluate Third Dose of Vaccine in Participants with Impaired Immune Systems
- COVID-19
Aug 25, 2021
Novavax Announces COVID-19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination
- COVID-19
Aug 5, 2021
Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine
- COVID-19
Aug 5, 2021
Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine
- COVID-19
Aug 4, 2021
Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine
- COVID-19
Jun 30, 2021
Novavax Statement on Proof of Vaccination for Phase 3 Clinical Trial Participants: Updated June 30, 2021
- Statement
- COVID-19
Jun 30, 2021
Novavax Statement on Completion of the National Research Council of Canada Biologics Manufacturing Centre
- Statement
- COVID-19
Jun 22, 2021
Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously
- COVID-19
- Seasonal Influenza
Jun 14, 2021
Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
- COVID-19
Jun 14, 2021
Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine
- COVID-19
Jun 11, 2021
Novavax to Participate in Panel at BIO Digital 2021
- COVID-19
Jun 7, 2021
Novavax to Participate in Jefferies Virtual Healthcare Conference
- COVID-19
May 27, 2021
Novavax to Present at International Society for Vaccines Virtual Congress COVID-19 Vaccine Update
- COVID-19
May 24, 2021
Novavax Announces Memorandum of Understanding to Explore Expansion of COVID-19 Vaccine Activities in South Korea
- COVID-19
May 22, 2021
Novavax Statement on Proof of Vaccination for Phase 3 Clinical Trial Participants in the United Kingdom
- Statement
- COVID-19
May 22, 2021
Complete Trial Results Manuscript of Novavax COVID-19 Investigational Vaccine Posted to Preprint Server medRxiv
- Statement
- COVID-19
May 21, 2021
Novavax Statement on Participation in Mix-and-Match COVID-19 Vaccine Booster Trial in the United Kingdom
- Statement
- COVID-19
May 21, 2021
Novavax Statement on Updated PREVENT-19 Trial Protocol
- Statement
- COVID-19
May 10, 2021
Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate
- COVID-19
- Seasonal Influenza
May 10, 2021
Novavax Statement on Ministry of Health, Labour and Welfare’s Announcement Regarding Procurement from Takeda of NVX-CoV2373 for Japan
- Statement
- COVID-19
May 7, 2021

Show per page